Clinical study For the Chronic Kidney Disease

Randomised Clinical Study To Evaluate The Efficacy Of Punarnavadi Ksheera Basti And Of Punarnava-Gokshuradi Ksheerabasti In Subject Of Chronic Kidney Disease(CKD). - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/098848

Enrollment

Registered

2025-12-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects who are fulfilling the objective criteria. 2. Subjects age between 18-70yrs, of either sex. 3. Subjects who are fit for Niruha Basti Karma. 4. Subjects with classical symptoms of CKD having clinical features of oedema, pruritis, generalized weakness, nausea, oliguria, loss of appetite, breathlessness, muscle cramps. 5. Diagnosed cases of CKD with GFR lies between 30-90 mL/min/1.73m2 and not on dialysis. 6. Subjects with Albuminuria(30-300mg) for more than 3 months. 7. Subjects with adequate Blood pressure control. 8. Subjects with adequate glycemic control.

Exclusion criteria

Exclusion criteria: 1. Subjects who are having Ama Lakshana. 2. Subjects of congenital renal diseases, Polycystic Kidney diseases, congenital nephrotic syndrome or any other congenital disorders. 3. Subjects having severe Agnimandya. 4. Pregnant women, lactating mother or post-partum subjects. 5. Subjects who are on dialysis, operated for renal transplantation. 6. Subjects with serious illness and on treatment, like cardiovascular diseases, acute/chronic mental disorders, serious organic diseases, comorbid Subjects, hepato-pancreatic diseases. 7. Evidence of active infection on the day of pretrial investigation with temperature more than 38 C or WBC more than or equal to 13,000 cells/µL. 8. History of malabsorption or any intestinal related pathology. 9. Under treatment or operated of Ca of rectum, kidneys, intestines or Subjects with any kind of malignancy. 10. Subjects who are on treatment for epileptic or any neurological pathologies, Subjects who are on anti-TB medications, or steroids for more than 6 months. 11. Subjects with history of any kind of pathologic conditions which hampers the study.

Design outcomes

Primary

Measure	Time frame
Improved Kidney Functions.Timepoint: 55 days	—

Secondary

Measure	Time frame
1. Improved GFR 2. Reduction in oedema. 3. Reduction in Pruritis. 4. Oliguria. 5. Pallor. 6. Anorexia. 7. Nausea. 8. Generalised weakness. 9. HaematuriaTimepoint: 55 Days	—

Countries

India

Contacts

Public ContactDr Upanishad

Ayurveda Mahavidyalaya And Hospital Hubli

ayurvasant@gmail.com9902749144

Outcome results